Stephen Hahn clearly makes a good first impression.
That much was clear when the Trump Administration’s nominee for Commissioner of the US Food & Drug Administration testified before...
US FDA Nominee Makes A Good First Impression, But This Is Still An Odd Transition
Listen to this article
Stephen Hahn mostly coasted through a confirmation hearing to be the next FDA commissioner – but he still didn’t really give any indication of why he wants the job.
Learn what's happening at the US FDA. On the go.
More from US FDA
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
• By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
• By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
More from Agency Leadership
• By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
• By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.